Loading clinical trials...
Loading clinical trials...
An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02
Conditions
Interventions
Oxabact OC5 - Oxalobacter formigenes Strain HC-1
Locations
8
United States
Vanderbilt University Hospital
Nashville, Tennessee, United States
Centre Hospitalier Universitaire de Liège
Liège, Belgium
Kindernierenzentrum Bonn
Bonn, Germany
Hospital Vall d'Hebron
Barcelona, Spain
Hédi Chaker University Hospital
Sfax, Tunisia
Sahloul University Hospital
Sousse, Tunisia
Start Date
March 14, 2019
Primary Completion Date
July 14, 2021
Completion Date
July 14, 2021
Last Updated
December 8, 2021
Lead Sponsor
OxThera
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions